Show results for
Refine by
Risk Of Disease Articles & Analysis
55 news found
The use of these marine oils significantly lowers cardiovascular disease risks and promotes general health. Alfa Chemistry offers multiple marine oil options such as fish oil, krill oil, cod liver oil, and algae oil which possess distinct nutritional advantages. ...
Such properties include anti-inflammatory effects, promotion of brain health, and reduction of cardiovascular risk. Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...
High-risk disease was defined using the LATITUDE criteria, which includes ≥2 risk factors: a Gleason score of ≥8, ≥3 bone lesions, and the presence of measurable visceral metastasis. Of 1,305 patients in the full analysis set, 1,005 (77%) had high-volume disease, 912 (70%) had high-risk ...
ByBayer AG
The goal of the dental infection control program is to reduce the risk of disease transmission and provide a safe environment for each patient working in a dental clinic or dental patient. ...
Leading a healthy lifestyle is about feeling good about yourself, reducing your risk of disease (and so much more). However, there are cases when you can’t wait too long or simply don’t have time to go to the gym. ...
We are very pleased with today’s outcome as we continue our mission to improve lives of people living with inflammatory diseases.” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), ...
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical trial, Flamingo-01, has officially started Multiple sites have begun the screening and enrolling process ...
Our goal is to reproduce the Phase IIb clinical trial results, which showed no metastatic breast cancer recurrences in patients treated with GLSI-100 over 5 years of follow-up, if the patients were treated, followed, and remained disease free over the first 6 months.” About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to ...
In order to increase the public awareness of cardiovascular health and encourage the population to take preventive action by identifying and mitigating the effects of cardiovascular disease (CVD) risk factors in a timely fashion, the online clinic Medon in collaboration with the health technology start-up Longenesis, has published a survey to determine the CVD ...
Abstract Number: TPS1110; Poster Number: 485b; Abstract Title: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 (Co-authored with Baylor College of Medicine) ...
Dry Eye Syndrome is a chronic disease that affects the productivity and quality of life of 1.52 billion people worldwide [1]. The COVID-19 pandemic has further exacerbated the problem, as prolonged time in front of screens is a risk factor for the disease. Other risk factors include aging, eye surgeries, dry environments, ...
Despite the availability of SARS-CoV-2 vaccines, there remains a need for oral drugs to treat the infection and prevent severe disease, especially in at-risk individuals. BIT225 has an established human safety profile and has the potential to be an important first-in-class drug for COVID-19 treatment. ...
It leaves many with undiagnosed and untreated levels of disease, and a higher risk of consequent visual loss and blindness, as is recognized by the strict HEDIS/MIPS requirements for the diabetic eye exam.[3],[4],[5],[6],[7],[8],[9],[10] “Primary care providers want access to the latest diagnostic tools so that testing can be offered during office visits ...
Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant will provide funding ...
The studies evaluated patients with R/R DLBCL, PMBCL and FL3B, including those with a broad range of histologies and high-risk disease, and patients who received Breyanzi in the inpatient and outpatient setting. ...
The experts of the Anti-Microbial Resistance (AMR) world, including Vaxdyn’s researchers, have been warning about the entrance into a post-antibiotic era or the occurrence of a silent pandemic for years. However, the general public, including health practitioners, did not understand the message or underscored the magnitude of the problem. Recently, a vast network of AMR experts around the ...
(NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. ...
To highlight the importance of lung cancer screening, Auris is sharing key insights from the report, and which groups may be at a higher risk for the disease. Important Statistics from the Report Just how common is lung cancer, and who is at risk? ...
Coala-Life Group AB (publ), a leading company in cloud-based remote monitoring of heart and lung diseases, announces today that the TITAN-DM study – a clinical observational study aimed at increasing knowledge about the incidence of atrial fibrillation in people with diabetes – is now fully recruited with 600 participants. ...